Richard W. Paul & Associates’s Novo Nordisk NVO Stock Holding History

Richard W. Paul & Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Buy	26,795 +26,775	+133,875%	+$1.15M	0.39%	70
2026 Q1	$735	Hold	20	–	–	﹤0.01%	292
2025 Q4	$1.02K	Hold	20	–	–	﹤0.01%	278
2025 Q3	$1.11K	Hold	20	–	–	﹤0.01%	302
2025 Q2	$1.38K	Hold	20	–	–	﹤0.01%	314
2025 Q1	$1.39K	Sell	20 -120	-86%	-$9.91K	﹤0.01%	308
2024 Q4	$12K	Buy	140 +20	+17%	+$2.16K	﹤0.01%	295
2024 Q3	$14.3K	Hold	120	–	–	0.01%	286
2024 Q2	$17.1K	Hold	120	–	–	0.01%	265
2024 Q1	$15.4K	Hold	120	–	–	0.01%	290
2023 Q4	$12.4K	Hold	120	–	–	0.01%	292
2023 Q3	$10.9K	Hold	120	–	–	0.01%	286
2023 Q2	$9.71K	Hold	120	–	–	﹤0.01%	317
2023 Q1	$9.55K	Hold	120	–	–	﹤0.01%	324
2022 Q4	$8.12K	Buy	+120	New	+$7.04K	﹤0.01%	337

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Richard W. Paul & Associates's NVO Position: Q2 2026 in Review

Richard W. Paul & Associates increased its Novo Nordisk (NVO) stake by 133,875% in Q2 2026, buying an estimated $1.15M and bringing the position to 26,795 shares worth $1.28M. The position accounts for 0.39% of the portfolio, ranked #70.

Richard W. Paul & Associates first reported a position in NVO in Q4 2022 and has held it in 15 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Richard W. Paul & Associates held 26,795 shares of Novo Nordisk worth $1.28M as of Q2 2026.
Richard W. Paul & Associates bought 26,775 Novo Nordisk shares in Q2 2026, an estimated $1.15M.
Novo Nordisk made up 0.39% of Richard W. Paul & Associates's portfolio in Q2 2026, its #70 holding.
Richard W. Paul & Associates first reported a position in Novo Nordisk in Q4 2022 and has held it in 15 quarters since.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Richard W. Paul & Associates's 13F filing for Q2 2026, filed 10 Aug 2026.